Inter-species differences in regulation of the progranulin&#8211;sortilin axis in TDP-43 cell models of neurodegeneration by V. Gumina et al.
 International Journal of 
Molecular Sciences
Article
Inter-Species Differences in Regulation of the
Progranulin–Sortilin Axis in TDP-43 Cell Models
of Neurodegeneration
Valentina Gumina 1, Elisa Onesto 1,†, Claudia Colombrita 1, AnnaMaria Maraschi 1,
Vincenzo Silani 1,2,3 and Antonia Ratti 1,4,*
1 Istituto Auxologico Italiano, IRCCS, Department of Neurology-Stroke Unit and Laboratory of Neuroscience,
Via Zucchi 18, 20095 Cusano Milanino, Milan, Italy; valegumina@gmail.com (V.G.);
elisa.onesto.eo@axxam.com (E.O.); claudiacolombrita@hotmail.com (C.C.); a.maraschi@auxologico.it (A.M.);
vincenzo@silani.com (V.S.)
2 Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, Università degli
Studi di Milano, Via F. Sforza 35, 20122 Milan, Italy
3 “Aldo Ravelli” Center for Neurotechnology and Experimental Brain Therapeutics, Università degli
Studi di Milano, Via A. di Rudinì 8, 20142 Milan, Italy
4 Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano,
Via Fratelli Cervi 93, 20090 Segrate, Milan, Italy
* Correspondence: antonia.ratti@unimi.it; Tel.: +39-02-619113045
† Current adress: Axxam Spa OpenZone, via A. Meucci 3, 20091 Bresso, Milan, Italy.
Received: 22 October 2019; Accepted: 20 November 2019; Published: 22 November 2019 
Abstract: Cytoplasmic aggregates and nuclear depletion of the ubiquitous RNA-binding protein
TDP-43 have been described in the autoptic brain tissues of amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTLD) patients and both TDP-43 loss-of-function and gain-of-function
mechanisms seem to contribute to the neurodegenerative process. Among the wide array
of RNA targets, TDP-43 regulates progranulin (GRN) mRNA stability and sortilin (SORT1)
splicing. Progranulin is a secreted neurotrophic and neuro-immunomodulatory factor whose
endocytosis and delivery to the lysosomes are regulated by the neuronal receptor sortilin. Moreover,
GRN loss-of-function mutations are causative of a subset of FTLD cases showing TDP-43 pathological
aggregates. Here we show that TDP-43 loss-of-function differently affects the progranulin–sortilin
axis in murine and human neuronal cell models. We demonstrated that although TDP-43 binding to
GRN mRNA occurs similarly in human and murine cells, upon TDP-43 depletion, a different control
of sortilin splicing and protein content may determine changes in extracellular progranulin uptake
that account for increased or unchanged secreted protein in murine and human cells, respectively.
As targeting the progranulin–sortilin axis has been proposed as a therapeutic approach for GRN-FTLD
patients, the inter-species differences in TDP-43-mediated regulation of this pathway must be
considered when translating studies from animal models to patients.
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1. Introduction
The ubiquitous TDP-43 RNA-binding protein (RBP) is the major component of the pathological
aggregates described in the autoptic brain tissues of the majority of amyotrophic lateral sclerosis (ALS)
patients and of a subset of frontotemporal lobar dementia (FTLD) cases [1,2]. Pathological TDP-43
aggregates are prevalently localized in the cytoplasm of affected neurons, which typically also show
a concomitant depletion of TDP-43 protein from the nucleus [1,2]. The pathobiology associated to
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TDP-43 therefore includes both gain- (GOF) and loss-of-function (LOF) mechanisms and a combination
of both is supposed to contribute to the neurodegenerative process in ALS/FTLD diseases [3].
TDP-43 regulates different steps of RNA metabolism both in the nucleus, where it is mainly
localized and controls splicing, and in the cytoplasm, where it is involved in mRNA transport, stability
and local translation [4]. A plethora of TDP-43 splicing and mRNA targets have been identified by
high-throughput approaches in physiological and disease states [5]. We and others found progranulin
(Grn) mRNA as a cytoplasmic target in murine experimental models with TDP-43 binding to its 3′UTR
sequence [6,7]. We also demonstrated that, upon TDP-43 LOF in motoneuronal-like NSC-34 cells,
Grn mRNA stability is increased, leading to an upregulation of progranulin (Pgrn) protein content [7].
Progranulin is a secreted glycoprotein expressed in the nervous system both in neuronal
and glial cells, where it mainly modulates neuroinflammation and acts as a neurotrophic factor,
promoting cell survival and neurite/axon growth [8]. Autosomal dominant LOF mutations in the
GRN gene are causative of familial (5–20%) and sporadic (1–5%) FTLD cases [9], which also present
with TDP-43 pathological aggregates in brain tissues [10], suggesting a mechanistic link between
GRN haploinsufficiency and TDP-43 pathology. Both in animal and cell models, Pgrn depletion was
shown to induce cytoplasmic TDP-43 mislocalization or accumulation of its C-terminal fragments and
to severely compromise neuronal survival and neurite formation [11–14].
The maintenance of progranulin levels is also important for lysosome activity, which is severely
affected in Grn knock-out mice [15] and in neuronal ceroid lipofuscinosis (NCL), a disease due to
rare recessive GRN LOF mutations [16,17]. In neurons, progranulin homeostasis and delivery to
lysosomes is regulated by its interaction with the transmembrane receptor sortilin (SORT1) [18],
recently identified as a rare genetic risk factor for FTLD [19]. Interestingly, TDP-43 also regulates
SORT1 gene expression [20] and alternative splicing, although producing different isoforms in mice
and in humans [6,21,22]. In particular, TDP-43 represses the inclusion of an intronic exon cassette
(exon 17b) which, in the case of TDP-43 LOF, generates a longer Sort1 protein with a function similar
to the main Sort1 isoform lacking the 33-aminoacidic region encoded by exon 17b (Sort1∆ex17b) in
mice [21]. In contrast, in humans, the inclusion of this exon cassette, although a rarer event than in
mice, introduces a premature stop codon leading to a non-functional and extracellularly released
SORT1 protein that may act as a decoy receptor, inhibiting PGRN endocytosis [21,22].
Therapeutic approaches for FTLD-GRN pathology aim to restore PGRN levels by the inhibition of
the SORT1–PGRN interaction. Indeed, the pharmacological or gene inhibition of SORT1 protein levels
has been associated with an increase of extracellular PGRN levels [18,23]. Moreover, PGRN treatment
or overexpression exerts a neuroprotective effect on cultured neurons [24] and is able to rescue neuronal
defects and TDP-43 aggregation both in zebrafish and mice models of TDP-43 pathology [25–27].
Given the TDP-43 regulatory activity on both GRN and SORT1 RNA, in this study we further
investigated the progranulin–sortilin axis in TDP-43 LOF cell models, evaluating if the secreted
progranulin levels, important for both its neurotrophic and lysosomal functions, are affected.
By comparing human and murine TDP-43 LOF neuronal cell models, we provide evidence that
TDP-43-associated regulatory mechanisms differ between mice and humans having a different impact
on progranulin bioavailability.
2. Results
2.1. Analysis of Intracellular and Secreted Pgrn Protein in Murine TDP-43 LOF and GOF Cell Models
We previously demonstrated that intracellular Pgrn levels are up-regulated by Tdp-43 LOF in
murine motoneuronal-like NSC-34 cells [7]. As extracellular progranulin is important to exert its
physiological functions in the nervous system, we investigated if Tdp-43 depletion also affects secreted
Pgrn levels. Upon Tdp-43 knock-down in NSC-34 cells (Figure 1a), we confirmed a significant 1.5-fold
increase of Pgrn protein content in cell lysates (Figure 1a,c) and a similar, although not significant, trend
for Grn gene expression (Figure 1b), as previously reported [7]. When we measured Pgrn content in the
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conditioned media by Western blot (WB) and ELISA assays, we observed a significant and similar
1.4-fold increase in secreted Pgrn in Tdp-43-knocked-down cells compared to control cells (Figure 1a,d).
To confirm that Tdp-43 depletion affects Pgrn protein content, we analyzed another murine neuronal
Tdp-43 LOF cell model. Upon Tdp-43 knock-down in murine neuroblastoma N2a cells, a significant
increase of both intracellular (2.1-fold) and secreted (1.6-fold) Pgrn protein levels were observed,
although Grn mRNA levels remained unchanged (Supplementary Figure S1), confirming the results
obtained in NSC-34 cells.
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Densitometric and statistical analysis of intracellular (CELL) Pgrn protein content shown in (a) (mean 
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experiments; two-tailed unpaired t test; ** p < 0.01). 
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Figure 1. Progranulin (Pgrn) protein content and secretion in murine TDP-43 loss-of-function (LOF)
cells. (a) Representative Western blot (WB) images (left panel) of Pgrn protein in cell lysates (CELL) and
conditioned media (CM) upon Tdp-43 knock-down (siTdp-43) in murine motoneuronal-like NSC-34
cells compared to negative control siRNA-transfected (siCTRL) cells. Densitometric analysis (right panel)
shows Tdp-43 gene silencing efficiency. αTUBULIN was used for intracellular data normalization and
as a non-secreted control protein in CM (mean ± s.e.m.; n = 5 independent experiments; two-tailed
unpaired t test; *** p < 0.001). (b) Real time PCR of Grn gene expression upon Tdp-43 depletion
(mean ± s.e.m.; n = 3 independent experiments; two-tailed unpaired t test). (c) Densitometric and
statistical analysis of intracellular (CELL) Pgrn protein content shown in (a) (mean ± s.e.m.; n = 5
independent experiments; two-tailed unpaired t test; * p < 0.05). (d) Secreted Pgrn levels detected in CM
by WB shown in (a) and by ELISA assays (mean ± s.e.m.; n = 4 independent experiments; two-tailed
unpaired t test; ** p < 0.01).
To assess if Tdp-43 affects Pgrn protein content specifically by a LOF mechanism, we also analyzed
Pgrn protein levels in a TDP-43 gain-of-function (GOF) model obtained by the ectopic expression of the
pathological TDP-43 C-terminal fragments (25 kDa and 35 kDa). Unlike the full-length TDP-43 protein,
which localized only in the nucleus as expected, we confirmed that the truncated 35 kDa and 25 kDa
TDP-43 proteins formed aggregates with a prevalent cytoplasmic localization (Figure 2a), mimicking
the pathological aggregation observed in ALS/FTLD brains [28]. To further characterize these TDP-43
GOF models and thereby exclude a loss of the endogenous TDP-43 function, we analyzed the splicing
pattern of the well-known TDP-43 target POLDIP3 [29,30]. When the recombinant GFP-TDP-43,
GFP-TDP-35 and GFP-TDP-25 proteins were over-expressed in NSC-34 cells, the main Poldip3 α
protein isoform was expressed similarly to the control condition (GFP) (Figure 2b), suggesting that the
endogenous Tdp-43 splicing activity is maintained in these TDP-43 GOF models in line with previous
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data [28]. In contrast, upon TDP-43 knock-down, we observed an increase of the Poldip3 β isoform
compared to control cells (Figure 2b) as expected [29]. When we measured Pgrn protein by WB assay
in TDP-43 GOF cells, we did not observe any difference in its level both in the cell lysates and the
conditioned media (Figure 2c). These data suggest that both intracellular and secreted Pgrn protein
levels are specifically affected by Tdp-43 LOF mechanism in murine neuronal NSC-34 and N2a cells.
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Figure 2. Pgrn r t tent and secretion in murine TDP-43 gain-of-fu ction (GOF) cells.
(a) ti e i unofluorescence images showing the subcellular localization of the recombinant
GFP-TDP-43 full ength C-terminal fragments (GFP-TDP-35; GF TDP-25) in NSC-34 cells.
DAPI (blue) was used for nuclei staining. Scale bar: 10 µm. (b) Representative WB imag s of
Poldip3 protein isoforms (α and β) in NSC-34 cells knocked-down for Tdp-43 (siTdp-43) or expressing
GFP-TDP-43, GFP-TDP-35 and GFP-TDP-25 constructs as indicated. Immunoblots with anti-GFP and
anti-Tdp-43 antibodies were performed to assess TDP-43 over-expression and gene silencing efficiencies,
respectively. Upon GFP-TDP-43 over-expression, autoregulation of the endogenous Tdp-43 protein
could be observed. αTubulin was used for sample normalization. (c) Representative WB images and
densitometric analyses of Pgrn protein content in cell lysates (CELL) and conditioned media (CM) of
NSC-34 cells transfected as indicated. αTubulin was used for sample normalization and as non-secreted
control protein in CM (mean± s.e.m.; n = 3 independent experiments; one-way ANOVA and Bonferroni’s
multiple comparison post hoc test) *, residual signal from previous anti-GFP hybridization.
2.2. Analysis of Intracellular and Secreted PGRN Protein in Human TDP-43 LOF and GOF Cell Models
To further investigate if the TDP-43-mediated regulation of Pgrn protein content observed in mice
is also conserved in humans, we first tested if TDP-43 is able to bind the human GRN mRNA as already
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proven in mice [7]. Alignment of the murine and human GRN 3′UTR sequences showed an overall 70%
identity (Supplementary Figure S2). In the human sequence, a 24-nucleotide long region including
a (TG)5 motif was predicted as the putative binding site for TDP-43 by in silico analysis with the
RBPmap software compared to the highly conserved murine region embedded with a (TG)6 motif
(Supplementary Figure S2).
We performed a UV-crosslinking immunoprecipitation (UV-CLIP) assay using a riboprobe
encompassing the human full-length GRN 3′UTR region (Supplementary Figure S2) and cell lysates
expressing the human recombinant Flag-TDP-43 protein. Our UV-CLIP assay showed that the TDP-43
protein binds to the human GRN 3′UTR similarly to the murine one (Figure 3a), suggesting the
conservation of post-transcriptional regulatory mechanisms between mice and humans on GRN mRNA.
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Figure 3. PGRN protein content and secretion in human TDP-43 LOF cells. (a) SDS-PAGE showing the
results of the UV-crosslinking immunoprecipitation (UV-CLIP) experiment using HEK293T protein
lysates overexpressing the human recombinant Flag-TDP-43 protein and the P32-radiolabelled murine
and human GRN 3′UTR riboprobes. The murine riboprobe was used as positive control and the anti-IgG
antibody as a negative control for immunoprecipitation. (b) Representative WB images showing
TDP-43 and PGRN immunoblots of cellular lysates (CELL) and conditioned media (CM) in human
M17 cells upon TDP-43 gene silencing. αTubulin was used for data normalization of intracellular
protein content and as non-secreted control protein in CM. (c) Real time quantification of GRN mRNA
upon TDP-43 knock-down in human neuroblastoma M17 cells (mean ± s.e.m.; n = 3 independent
experiments; two-tailed unpaired t test; ** p < 0.01). (d) Densitometric and statistical analysis of WB
data shown in b) (mean ± s.e.m.; n = 5 independent experiments; two-tailed unpaired t test; * p < 0.05;
*** p < 0.001).
To further investigate the regulatory activity of TDP-43 on PGRN in human cells, we analyzed
the effects of TDP-43 LOF on cellular and secreted PGRN protein content in human neuroblastoma
M17 cells. TDP-43 knock-down (Figure 3b,d) promoted a significant 1.8-fold increase of GRN mRNA
levels (Figure 3c), also suggesting that human TDP-43 may act to reduce GRN mRNA stability as already
demonstrated in mice [7]. When we evaluated changes at protein level, we observed a significant
1.9-fold increase of the intracellular PGRN levels (Figure 3b,d) in line with the mRNA data (Figure 3c)
and similarly to Pgrn protein content in murine TDP-43 LOF cells (Figure 1). However, when we
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analyzed the secreted PGRN levels, we detected no changes upon TDP-43 knock-down (Figure 3b,d),
in contrast with the murine LOF cell model (Figure 1).
To investigate if PGRN content is affected specifically by a TDP-43 LOF mechanism in humans
similarly to mice, we reproduced a TDP-43 GOF model in human neuroblastoma M17 cells
by the overexpression of the pathological TDP-43 C-terminal fragments (35 kDa and 25 kDa).
By immunofluorescence analysis, we observed that the ectopic full-length TDP-43 protein localized
in the nucleus and the 35 kDa and 25 kDa TDP-43 C-terminal fragments formed mainly cytoplasmic
aggregates (Figure 4a) as in the murine NSC-34 cells (Figure 2a). WB analyses of intracellular and
secreted PGRN protein levels did not show any difference in TDP-43 GOF models (Figure 4b),
suggesting that also in human neuronal-like cells, PGRN regulation is impaired only by TDP-43
depletion, similarly to murine cells.
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Figure 4. PGRN protein content and secretion in human TDP-43 GOF cells. (a) Representative
immunofluorescence images showing the subcellular localization of the recombinant GFP-TDP-43
full-length and C-terminal fragments (GFP-TDP-35; GFP-TDP-25) in human neuroblastoma M17
cells. DAPI (blue) was used for nuclei staining. Scale bar: 10 µm. (b) Representative WB images and
densitometric analyses of PGRN protein content in cell lysates (CELL) and conditioned media (CM) of
M17 cells transfected as indicated. Anti-GFP immunoblot shows the transfection efficiency andαTubulin
was used for sample normalization of the intracellular protein content and as non-secreted control
protein in CM (mean ± s.e.m.; n = 3 independent experiments; one-way ANOVA and Bonferroni’s
multiple comparison post hoc test).
Int. J. Mol. Sci. 2019, 20, 5866 7 of 16
2.3. Analysis of Sortilin Splicing and Protein Levels upon TDP-43 LOF in Murine and Human
Neuronal Cell Models
As the secreted progranulin levels differ between the human and the murine TDP-43 LOF neuronal
cell models, we hypothesized that these differences could be explained by a different progranulin
uptake via its main neuronal transmembrane receptor, sortilin (SORT1), whose alternative splicing is
described to be differently regulated by TDP-43 in mice and humans [21,31]. We analyzed sortilin gene
expression and exon 17b alternative splicing by real time PCR in both murine motoneuronal-like NSC-34
and human neuroblastoma M17 cells knocked-down for TDP-43 (Figure 5). In murine NSC-34 cells, we
observed that TDP-43 gene silencing induced a significant 1.8-fold increase of the Sort1ex17b isoform
with unchanged overall expression of the Sort1 gene (Figure 5a), similarly to what we observed in
another murine neuronal-like cell model, the neuroblastoma N2A cells (Supplementary Figure S3), and
confirming previous literature data [6,21]. In contrast, upon TDP-43 depletion in human neuroblastoma
M17 cells, overall SORT1 mRNA levels significantly increased 1.4 fold, as we previously described [20],
mainly due to an increase of the main SORT1∆ex17b isoform (Figure 5b) as the SORT1ex17b isoform
represents a rare splicing isoform in human cells [21]. By analyzing SK-N-BE neuroblastoma cells as
an alternative human neuronal cell model, we observed the same SORT1 gene expression pattern of
M17 cells (Supplementary Figure S4a).
Int. J. Mol. Sci. 2019, 20, x 7 of 16 
 
control protein in CM (mean ± s.e.m.; n = 3 independent experiments; one-way ANOVA and 
Bonferroni’s multiple comparison post hoc test). 
2.3. Analysis of Sortilin Splicing and Protein Levels upon TDP-43 LOF in Murine and Human Neuronal 
C ll Models 
As the secreted progranulin levels differ between the human and the murine TDP-43 LOF 
neuronal cell models, we hypothesized that these differe ces could be explained by a different 
pr granulin up ake via i s main neuronal transmembrane receptor, sortilin (SORT1), whose 
alternative splicing is described to be differently regulated by TDP-43 in mice and humans [21,31]. 
We analyzed sortilin gene expression and exon 17b alternative splicing by real time PCR in both 
murine motoneuronal-like NSC-34 and human neuroblastoma M17 cells knocked-down for TDP-43 
(Figure 5). In murine NSC-34 cells, we observed that TDP-43 gene silencing induced a significant 1.8-
fold increase of the Sort1ex17b isoform with unchanged overall expression of the Sort1 gene (Figure 
5a), similarly to what we observed in another murine neuronal-like cell model, the neuroblastoma 
N2A cells (Supplementary Figure S3), and confirming previous literature data [6,21]. In contr st, 
upon TDP-43 depletion in human neuroblastoma M17 cells, overall SORT1 mRNA levels 
significantly increased 1.4 fold, as we previously described [20], mainly due to an increase of the main 
SORT1Δex17b isoform (Figure 5b) as the SORT1ex17b isoform represents a rare splicing isoform in 
human cells [21]. By analyzing SK-N-BE neuroblastoma cells as an alternative human neuronal cell 
model, we observed the same SORT1 gene expression pattern of M17 cells (Supplementary Figure 
S4a). 
 
Figure 5. Regulation of sortilin gene expression, splicing and protein levels in human and murine 
TDP-43 LOF cells. Real time quantification of total Sortilin and of the splicing isoforms (∆ex17b and 
ex17b) transcripts upon TDP-43 depletion by siRNA in (a) NSC-34 cells and (b) M17 cells (mean ± 
s.e.m.; n = 3 independent experiments; two-tailed unpaired t test; * p < 0.05, ** p < 0.01). Representative 
Figure 5. Regulation of sortilin gene expression, splicing and protein levels in human and murine
TDP-43 LOF cells. Real time quantification of total Sortilin and of the splicing isoforms (∆ex17b and ex17b)
transcripts upon TDP-43 depletion by siRNA in (a) NSC-34 cells and (b) M17 cells (mean ± s.e.m.;
n = 3 independent experiments; two-tailed unpaired t test; * p < 0.05, ** p < 0.01). Representative
WB and densitometry analyses of intracellular sortilin protein levels in (c) NSC-34 and (d) M17 cells.
Immunoblots with TDP-43 antibody were shown to assess gene silencing efficiencies. αTubulin was
used for sample normalization (mean ± s.e.m.; n = 5 independent experiments; two-tailed unpaired
t test; * p < 0.05). WB and densitometric data of sortilin protein detected in the conditioned media (CM)
of e) NSC-34 and f) M17 cells knocked-down for TDP-43. αTubulin was used as a negative control in
CM (mean ± s.e.m.; n = 4 independent experiments; two-tailed unpaired t test; * p < 0.05).
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When we analyzed Sort1 at the protein level in murine LOF cells, we observed that the total
protein amount did not change in comparison with cells transfected with a control siRNA (Figure 5c,
Supplementary Figure S3b). Instead, in human M17 cells, TDP-43 LOF led to a significant 1.9-fold
increase in total SORT1 protein levels (Figure 5d), which was also confirmed in human neuroblastoma
SK-N-BE cells (Supplementary Figure S4b).
As previous literature data showed that both the human and murine sortilin protein
may be proteolytically cleaved and extracellularly released by the shedding mechanism [21,32],
we also quantified soluble sortilin protein levels in the conditioned media by WB assay. In both
murine and human cell models, the secreted sortilin protein showed a lower molecular weight
(approximately 100 kDa) with respect to the intracellular sortilin protein (>100 kDa) (Figure 5e,f;
Supplementary Figures S3c and S4c), corresponding to the soluble sortilin ectodomain after the
proteolytic cleavage [21,32]. Upon Tdp-43 knock-down in murine NSC-34 cells, we observed
a significant 3-fold increase in the secreted Sort1 protein (Figure 5e), supporting the hypothesis
that the Sort1ex17b isoform, the one mainly expressed upon Tdp-43 knock-down, may be more
accessible to protease cleavage and consequently more released extracellularly [21]. Similar results
were obtained in murine N2a cells, where a 5-fold increase in Sort1 protein in the conditioned media
was observed (Supplementary Figure S3c). However, in human M17 cells, the extracellular SORT1
protein level did not change upon TDP-43 depletion (Figure 5f), although its total intracellular content
increased (Figure 5d). Similar results were obtained when we analyzed SORT1 in the conditioned
media of human SK-N-BE cells (Supplementary Figure S4c). Altogether, our results show that sortilin
receptor splicing and protein content is differently regulated by TDP-43 LOF in murine and human cell
models and this may account for the observed inter-species differences in secreted progranulin levels.
3. Discussion
In this study we found that TDP-43 LOF differently affects the progranulin–sortilin axis in murine
and human cell models, which has an impact on secreted progranulin levels. In particular, we showed
that in both murine and human neuronal-like cells the intracellular and extracellular progranulin
protein levels are affected specifically by a TDP-43 LOF, while the presence of TDP-43 cytoplasmic
aggregates seems not to influence progranulin homeostasis. In particular, we observed an increase
of the intracellular progranulin protein levels both in murine and human TDP-43 knocked-down
cells, while the secreted progranulin content was upregulated in the two murine cell models and
was unchanged in the human ones. Our data show that the inter-species differences in progranulin
bioavailability may be explained by a different TDP-43-dependent regulation of gene expression and
splicing of the Sortilin gene and by the subsequent different distribution of the sortilin receptor both
intracellularly and extracellularly (Figure 6).
We previously described that TDP-43 post-transcriptionally regulates the Grn gene by binding to
its 3′UTR sequence and promoting its mRNA instability in murine NSC-34 cells [7], confirming previous
data that identified Grn as an in vivo RNA target of TDP-43 in the adult mouse brain, where TDP-43
depletion causes an increase in Grn mRNA [6]. Given the high conservation between murine and
human 3′UTR sequences, here we showed that TDP-43 binding to human GRN mRNA is conserved and
that TDP-43 depletion upregulates GRN gene expression, suggesting that TDP-43-mediated regulation
of GRN mRNA instability is also likely to be maintained in humans. Indeed, recent findings have
demonstrated that TDP-43 promotes GRN mRNA instability by acting on the deadenylation process
in human cell models [33]. In rodent and human models, TDP-43 is known to regulate the stability
of other mRNAs, with either destabilizing (VEGF and Tau) [7,34] or stabilizing (NEFL, HDAC6 and
Add2) [35–37] effects. Although splicing regulation is the main TDP-43 function [4] TDP-43 LOF may
also contribute to the neurodegenerative process in ALS and FTLD by different regulatory mechanisms,
including the control of mRNA stability and translatability.
When we also investigated the effects of TDP-43 LOF on GRN mRNA at the protein level,
we observed that an increase in mRNA content was associated with higher levels of intracellular
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progranulin in both human and murine TDP-43-depleted cells, thus supporting similarity between
humans and mice in progranulin regulation. As progranulin is a secreted glycoprotein, whose main
functions depend on its extracellular bioavailability [8], we also evaluated its content in conditioned
media and we observed that while murine TDP-43 LOF cells showed a parallel increase of extracellular
Pgrn levels, no changes of secreted PGRN were detected in the media of TDP-43 LOF human cells.
We therefore speculated that the already reported inter-species differences in regulation of Sortilin gene
expression and splicing mediated by TDP-43 might account for the different effects on extracellular
progranulin availability [20,21] (Figure 6).
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In murine motoneuronal-like NSC-34 cells, we confirmed that TDP-43 depletion induces Sort1
splicing changes with an upregulation of the longer Sort1ex17b isoform as already described in adult
mouse brain and in murine neuroblastoma N2a cells [6,21,38], but without changes of total intracellular
Sort1 protein levels, thus suggesting that progranulin uptake via sortilin is not affected by TDP-43
knock-down in mice. In contrast, in human TDP-43-depleted cells, we observed an increase of the
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main SORT1∆17b isoform, as previously described [20], and also of the intracellular SORT1 protein
levels, suggesting a possible up-regulation of PGRN uptake by the sortilin receptor that may account
for the differences between mice and humans in the availability of extracellular progranulin. Indeed,
upon TDP-43 knock-down in murine cells, the increase of extracellular PGRN levels probably depends
on a more active secretory pathway while, in human cells, the upregulation of intracellular SORT1
content also favors PGRN uptake, balancing secretion and resulting in unchanged extracellular PGRN
levels (Figure 6).
In humans the inclusion of the alternative SORT1 exon 17b has been described as a less frequent
splicing event than in mice, because other RBPs, such as hnRNP L, PTB/nPTB and hnRNP A1/A2, were
recently found to participate together with TDP-43 to inhibit human alternative exon 17b splicing [31].
The human truncated SORT1ex17b protein isoform is extracellularly released and is supposed to act
as a pathological “decoy receptor”, sequestering the extracellular PGRN [21]. Importantly, the main
SORT1∆ex17b protein isoform undergoes shedding, a proteolytic cleavage and extracellular release
of the large sortilin ectodomain, which still maintains the capacity to bind its ligands [21,39,40].
Sortilin shedding and extracellular release is an important mechanism to regulate the bioavailability
of its ligands, including progranulin and BDNF [32], in the extracellular milieu. In our human
TDP-43-depleted cells, the cleaved and extracellularly released SORT1 protein slightly decreased,
suggesting that both shedding and the SORT1ex17b isoform do not influence PGRN bioavailability,
which may rather be influenced by the increased intracellular SORT1 receptor. On the other hand,
in murine TDP-43 LOF cells, extracellular sortilin increased by 3- and-5- fold in NSC-34 and N2a
cells, respectively, in contrast to the unchanged cellular sortilin content, probably because the longer
Sort1ex17b isoform, efficiently generated upon TDP-43 depletion, is suggested to be preferentially
cleaved through the shedding mechanism [21]. Therefore, our data suggest that in murine models,
conversely to human ones, the extracellularly released sortilin protein may influence progranulin
bioavailability rather than the intracellular receptor.
Maintenance of progranulin homeostasis in the nervous system has a pivotal role because
decreased progranulin levels may increase neuronal susceptibility to different stressors, which may
lead to TDP-43 cleavage and aggregation by autophagy impairment and apoptosis activation [11–13,41].
Conversely, progranulin overexpression was shown to be neuroprotective in TDP-43 disease models
in vivo, because it is able to rescue neuronal defects and TDP-43 aggregation [25–27]. Here we confirm
a direct correlation between extracellular progranulin and extracellular cleaved sortilin levels [42] both
in humans and mice, although TDP-43 LOF, by differentially regulating Sortilin splicing and protein
isoform generation, has a different effect on progranulin bioavailability in human versus murine
neuronal cells.
Interestingly, the inhibition of PGRN interaction with SORT1 enhances the secreted PGRN
levels [18] and the progranulin–sortilin axis has been proposed as a promising therapeutic target to
increase PGRN levels in GRN-mutated FTLD patients by inhibiting SORT1 expression or its binding
affinity to PGRN using small molecules [23]. As the translation of pre-clinical studies in mice to clinical
trials is often unsuccessful [43], probably due to inter-species differences, our findings do show different
regulatory mechanisms in the progranulin–sortilin axis and suggest that a therapeutic modulation of
this pathway may lead to different outcomes in ALS/FTLD mouse models and in patients.
4. Materials and Methods
4.1. Cell Culture
Mouse motoneuronal-like NSC-34 cells, a hybrid cell line obtained by fusion of the mouse
neuroblastoma cells with motor neuron enriched, embryonic mouse spinal cord cells [44],
were maintained in DMEM medium supplemented with 5% fetal bovine serum (FBS, Sigma-Aldrich,
St. Louis, MO, USA), 1 mM sodium pyruvate, 100 units/mL penicillin, and 100 µg/mL streptomycin.
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Mouse neuroblastoma Neuro-2a cells were cultured in DMEM medium supplemented with 10%
FBS, 100 units/mL penicillin, 100 µg/mL streptomycin and 2.5 µg/mL of amphotericin b (Sigma-Aldrich).
Human neuroblastoma M17 and SK-N-BE cells were cultured in RPMI-1640 medium supplemented
with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 2 g/l glucose, 100 U/mL penicillin
and 100 µg/mL streptomycin. Trypsin-EDTA (Sigma-Aldrich) was used to split NSC-34, M17 and
SK-N-BE cells.
All neuronal-like cell lines were used in experiments without inducing further neuronal differentiation.
Human embryonic kidney (HEK) 293T cell line was maintained in DMEM supplemented with
10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin. All media and reagents were from Thermo
Scientific if not differently specified.
4.2. Plasmid Constructs and Cell Transfection
For loss-of-function experiments, gene silencing was performed using siRNA duplexes for mouse
TDP-43 (Sigma) and for human TDP-43 (Ambion, Thermo Fisher Scientific, Waltham, MA, USA),
as reported in [7,20]. Stealth RNAi Negative Control Low GC (Life Technologies) was used as control
siRNA. For the experiments, 1.5 × 105 cells/well were plated in 6-well plates and silenced in a double
round using Lipofectamine 2000 (Thermo Fisher Scientific). NSC-34 and Neuro-2a cells were harvested
after 96 h of gene silencing with the siRNA duplex (40 nM), while M17 and SK-N-BE cells were silenced
with siRNA duplex (80 nM) for 72 h. For quantification of secreted progranulin levels, the culture
medium was replaced by Optimem (Thermo Fisher Scientific) 16 h before harvesting cells.
For the gain-of-function experiments, 2 × 105 NSC-34 or M17 cells/well were seeded in 6-well
plates for Western blotting and on glass coverslips for the immunostaining assay and transiently
transfected with 3 µg of pGFPC2 empty vector (AddGene, Watertown, MA, USA), pGFPC2-hTDP-43,
pGFPC2-hTDP-35 or pGFPC2-hTDP-25 (all a kind gift of Dr. E. Buratti, ICGEB, Trieste). After a 48 h
transfection, cells for immunostaining were fixed in 4% paraformaldehyde in phosphate buffered
saline (PBS, pH 7.4, Santa Cruz Biotechnology, Dallas, TX, USA) for 20 min at room temperature (RT).
Differently, for Western blot analyses, cells were harvested, used to generate lysate and processed as
described below.
For UV-CLIP assays, 1.5× 106 HEK293T cells were seeded in a 100 mm dish, transiently transfected
with 6 µg of pFlag-CMV2-hTDP-43 (a kind gift of Dr. E. Buratti, ICGEB, Trieste, Italy), harvested 24 h
after transfection and used to generate lysate for protein extraction, as described below.
4.3. Western Blot Assay
Protein lysates were obtained by homogenizing cells in lysis buffer (150 mM NaCl, 20 mM Tris–HCl
pH 7.4, 1% Triton X-100, protease inhibitor cocktail (Roche Italia, Monza, Italy). Protein lysates were
incubated for 15 min on ice and then quantified by BCA protein assay (Thermo Fisher Scientific).
Protein samples (25 µg) were resolved by SDS-PAGE on 10% NuPAGE Bis-Tris pre-cast polyacrylamide
gels (Thermo Fisher Scientific) and transferred to nitrocellulose membranes (pre-cast iBlot Transfer
Stack, Thermo Fisher Scientific).
For the quantification of secreted progranulin, centrifugation of the conditioned media at
4000× g for 5 min was performed to remove debris and dead cells and the supernatants were collected.
One-fifth of the total medium was precipitated overnight at −20 ◦C in four volumes of cold acetone.
The day after, media were centrifuged at 15,000× g at 4 ◦C for 30 min and pellets were resuspended in
SDS-loading buffer and resolved by SDS-PAGE as described above.
Specific primary antibodies (reported in Supplementary Table S1) diluted in blocking solution
(5% milk in TBS (Santa Cruz Biotechnology) with 0.1% Tween-20 (Sigma-Aldrich)) were used
to perform immunoblots and chemiluminescence detection was obtained by the Novex ECL kit
(Thermo Fisher Scientific). Quantity One software (Biorad, Hercules, CA, USA) was used for
densitometric analyses. For quantification of secreted progranulin, the densitometric raw data
were normalized on the total protein amount of the corresponding cellular lysate.
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4.4. ELISA Assay
The mouse progranulin ELISA Kit (Adipogen_AG-45A-0019Y, San Diego, CA, USA) was used
to quantify the Pgrn protein content in the conditioned media of NSC-34 cells upon TDP-43
knockdown and a 1/25 of the total conditioned medium was used for quantification according
to the manufacturer’s instruction.
4.5. RNA Isolation, Reverse Transcription (RT) and Real Time PCR
Total RNA was obtained using TriZol reagent (Thermo Fisher Scientific) following the
manufacturer’s instructions. Total RNA from NSC-34/N2a (1 µg) and M17/SK-N-BE (3 µg) cells
was treated with 1 U DNaseI (Roche) for 20 min at 37 ◦C and retro-transcribed using oligodT and 1 U
SuperScript II-RT (Thermo Fisher Scientific).
Real time PCR was performed with SYBR Green PCR Master mix (Applied Biosystems, Thermo
Fisher Scientific) on QuantStudio 12 K Flex (Applied Biosystems) and the primer sequences used for
human and mouse Grn, total Sort1, Sort1∆ex17b and Sort1ex17b isoforms, and RPL10a genes are listed
in Supplementary Table S2. Threshold cycles (Ct) of the housekeeping RPL10a gene were used to
normalize the Ct value (∆Ct) for each tested gene and every experimental sample was referred to the
mean ∆Ct of the controls (∆∆Ct). Fold change values were expressed as 2−∆∆Ct.
4.6. Immunofluorescence and Image Acquisition
Cells were fixed as described above were then washed twice in 1×PBS for 10 min and permeabilized
in 0.3% Triton X-100 (Sigma) in 1× PBS (Gibco, Thermo Fisher Scientific) for 5 min at RT. After blocking
buffer (5% of Normal Goat Serum (Gibco) in PBS,) for 30 min at RT, incubation with anti-GFP antibody
(1:300; Roche) was performed for 90 min at 37 ◦C. Anti-mouse IgG Alexa Fluor 488 (1:500, Thermo
Fisher Scientific) was used as secondary antibody and coverslips were mounted onto glass slides using
Prolong Gold antifade reagent with DAPI (Thermo Fisher Scientific). A confocal inverted microscope
(Nikon Eclipse C1) was used to acquire Z-stacks images (0.2 µm) with a 60×magnification.
4.7. Nucleotide Sequence Alignment and in silico Analysis
The nucleotide sequence alignment of human (NM_002087.3) and murine (NM_008175.5) GRN
3′UTR was performed by the online pairwise sequence alignment EMBOSS Needle software. The online
RBPmap software (http://rbpmap.technion.ac.il [45]) was used to predict the putative TDP-43 binding
region in the human GRN 3′UTR. A stringent cut-off (≥5) was set for the Z-score value.
4.8. UV-Cross-Linking and Immunoprecipitation (UV-CLIP)
The 3′UTR region sequence of human GRN (322 pb) was amplified by RT-PCR from SK-N-BE
total RNA using the primers listed in Supplementary Table S2, cloned into the TOPO TA vector
(Thermo Fisher Scientific) downstream of the T7 promoter and linearized (0.5 µg) by HindIII restriction
enzyme (30 U) for in vitro transcription. The mouse Grn 3′UTR probe [7] was used as a positive control.
UV-crosslinking was performed using HEK293T protein lysates (200 µg) transfected with human
Flag-TDP-43 and 32P-radiolabeled riboprobes, as previously described [46]. Immunoprecipitation was
conducted on UV-crosslinked samples using the anti-FLAG (2 µg; Sigma-Aldrich) or the anti-IgG
antibodies (2 µg, SantaCruz Biotechnology) (Supplementary Table S1) and protein G Dynabeads
(Thermo Fisher Scientific). Immunocomplexes were washed several times in PBS with 0.02% Tween-20,
run on a 10% SDS-PAGE gel and analyzed by autoradiography.
4.9. Statistical Analyses
Statistical analyses were performed using two-tailed unpaired student’s t test or one-way ANOVA,
followed by appropriate post-hoc tests to compare two or multiple groups, using the GraphPad PRISM
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5 software package. Data were presented as mean ± standard error of mean (s.e.m.) of at least three
independent experiments and significance value was defined as * p < 0.05, ** p < 0.01, *** p < 0.001.
5. Conclusions
Our results show that the progranulin–sortilin axis is differently affected by TDP-43 loss-of-function
in mice and humans because although the TDP-43-dependent regulation of Progranulin mRNA is
conserved, the different control of sortilin gene expression, splicing, protein cleavage and extracellular
release strongly influences the bioavailability of extracellular progranulin in the two species.
As the progranulin–sortilin axis has been proposed as a novel therapeutic target in ALS/FTLD,
inter-species differences in regulatory mechanisms associated to the TDP-43 protein should be carefully
considered when translating preclinical data obtained in mouse disease models to patients.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/23/
5866/s1.
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Abbreviations
ALS amyotrophic lateral sclerosis
FTLD frontotemporal lobar dementia
RBP RNA-binding protein
TDP-43 TAR DNA binding protein 43
PGRN progranulin
SORT1 sortilin 1
LOF loss of function
GOF gain of function
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